✦ LIBER ✦

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Scribed by Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Sequist; Jean-Charles Soria; Joachim von Pawel; Brian Schwartz; Reinhard Von Roemeling; Alan B. Sandler

Book ID: 119218672
Publisher: CIG Media Group, LP.
Year: 2012
Tongue: English
Weight: 332 KB
Volume: 13
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2012.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1BA Phase III study of pemetrexed plus c

1BA Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

✍ C. Manegold; R. Digumarti; M. Zukin; F. de Marinis; A. Mellemgaard; D. Gandara; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB

A multicenter, randomized, phase III stu

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

✍ Roszkowski, Kazimierz; Pluzanska, Anna; Krzakowski, Maciej; Smith, Alexander Pet 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB